The use of immunotherapy for the treatment of both solid and hematologic malignancies is
now well established. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in the …

Immune checkpoint inhibitors are an integral part of cancer therapy following the
demonstration of substantial responses across multiple tumour types. These agents induce …

Immune checkpoint inhibitor therapy has forever changed the way we treat cancer.
However, with that, the adverse events associated with this class of agents has brought new …

Immune checkpoint inhibitor (ICI) therapy provides a valuable treatment option for many
cancer patients but is associated with immune-related adverse events (irAEs) that can …

New immunotherapies have significantly improved survival in certain advanced cancers in
recent years, particularly metastatic melanoma and lung cancer. The most effective of these …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

The use of immunotherapy for the treatment of both solid and hematologic malignancies is
widespread. Immune checkpoint inhibitors in particular have demonstrated considerable …

Immune checkpoint inhibitors that remove the 'brakes' on the body's immune system,
enhancing its attack on cancer cells, have revolutionised the treatment of many cancers …

Abstract Purpose of Review The unleashing of the immune system in an effort to fight cancer
has proven to be an incredible advance in the war on cancer. However that breakthrough …

Immune checkpoint inhibitors (ICIs) have significantly driven the oncology treatment
landscape as they immensely shift better clinical outcomes among various type of cancers …